10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
22.68
+0.63 (2.86%)
At close: Jan 21, 2026, 4:00 PM EST
22.75
+0.07 (0.31%)
After-hours: Jan 21, 2026, 7:42 PM EST
10x Genomics Stock Forecast
Stock Price Forecast
The 14 analysts that cover 10x Genomics stock have a consensus rating of "Hold" and an average price target of $15.61, which forecasts a -31.17% decrease in the stock price over the next year. The lowest target is $6.50 and the highest is $22.
Price Target: $15.61 (-31.17%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for 10x Genomics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Hold | 4 | 5 | 5 | 6 | 8 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 11 | 12 | 12 | 13 | 13 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Hold Maintains $15 → $18 | Hold | Maintains | $15 → $18 | -20.63% | Jan 7, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $19 → $20 | Strong Buy | Maintains | $19 → $20 | -11.82% | Dec 22, 2025 |
| Barclays | Barclays | Buy Maintains $17 → $22 | Buy | Maintains | $17 → $22 | -3.00% | Dec 15, 2025 |
| Citigroup | Citigroup | Strong Buy → Hold Downgrades $18 | Strong Buy → Hold | Downgrades | $18 | -20.63% | Dec 11, 2025 |
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $17 → $20 | Buy → Hold | Downgrades | $17 → $20 | -11.82% | Dec 2, 2025 |
Financial Forecast
Revenue This Year
640.79M
from 610.79M
Increased by 4.91%
Revenue Next Year
617.77M
from 640.79M
Decreased by -3.59%
EPS This Year
-0.48
from -1.52
EPS Next Year
-0.96
from -0.48
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 674.9M | 660.0M | ||||
| Avg | 640.8M | 617.8M | ||||
| Low | 618.3M | 584.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 10.5% | 3.0% | ||||
| Avg | 4.9% | -3.6% | ||||
| Low | 1.2% | -8.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.41 | -0.56 | ||||
| Avg | -0.48 | -0.96 | ||||
| Low | -0.99 | -1.18 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.